A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr¨om macroglobulinemia: the ASPEN study

A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstörm macroglobulinemia: the ASPEN studyö

Constantine S. Tam et al.